The Portland-based biopharmaceutical company has licensed the U.S. rights for Zuplenz, an oral film that contains an anti-nausea medication, ondansetron.
The Portland-based biopharmaceutical company has licensed the U.S. rights for Zuplenz, an oral film that contains an anti-nausea medication, ondansetron.
There’s a $1 billion market for the class of drugs to which the active ingredient belongs.
To take ondansetron, patients currently must swallow a pill and hold it down long enough to be digested, Galena President/CEO Mark Ahn said.
Read more at Portland Business Journal
